Oxford Biodynamics — First pharma agreement for EpiSwitch Orion

(LSE:OBD) Oxford BioDynamics has signed its first commercial pharmaceutical agreement with Johnson & Johnson. The agreement is to deploy Oxford BioDynamics' EpiSwitch Orion platform in a genotype-based biomarker discovery programme for inflammatory bowel disease. The project will process several hundred genotyped patient samples. The aim is to develop a predictive classifier of response to biologic therapy. The programme will use a training cohort and an independent blinded validation cohort. Financial terms of the agreement are undisclosed. Oxford BioDynamics describes the deal as commercial validation of the Orion platform. The company expects additional commercial agreements in the future. These future agreements could drive revenue visibility and partner-led growth. Johnson & Johnson is the counterparty in this agreement. The EpiSwitch Orion platform is being used specifically for genotype-based biomarker discovery. The project focuses on inflammatory bowel disease. The classifier to be developed will predict response to biologic therapy. The agreement is characterized as the first commercial pharmaceutical agreement for the Orion platform. The company highlights the potential for future revenue and growth from similar agreements.

Unknown